3.08

8.07% 0.23

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $3.08, with a volume of 882.47K. It is up +8.07% in the last 24 hours and down -0.65% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Previous Close:

$2.85

Open:

$2.86

24h Volume:

882.47K

Relative Volume:

0.47

Market Cap:

$330.85M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-2.75

EPS:

-1.12

Net Cash Flow:

$-120.82M

1W Performance:

+17.56%

1M Performance:

-0.65%

6M Performance:

-66.77%

1Y Performance:

-71.82%

1-Day Range:

$2.86

$3.10

1-Week Range:

$2.60

$3.10

52-Week Range:

$2.585

$13.01

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

140

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	3.08	330.85M	42.51M	-116.49M	-120.82M	-1.12
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Jan 15, 2025

Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St

Jan 15, 2025

Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 15, 2025

Jan 13, 2025

Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks

Jan 13, 2025

Jan 08, 2025

Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 08, 2025

Jan 04, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jan 04, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat

Jan 04, 2025

Jan 03, 2025

Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 03, 2025

Jan 01, 2025

Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 01, 2025

Dec 31, 2024

Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 31, 2024

Dec 24, 2024

State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 24, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat

Dec 24, 2024

Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $580,000 Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 21, 2024

Dec 17, 2024

The Manufacturers Life Insurance Company Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 17, 2024

Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com India

Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa

Dec 14, 2024

Dec 13, 2024

TNGX Stock Hits 52-Week Low at $2.7 Amid Market Challenges - Investing.com UK

Dec 13, 2024

Dec 10, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Dec 10, 2024

Dec 07, 2024

Cantor Fitzgerald Reaffirms Overweight Rating for Tango Therapeutics (NASDAQ:TNGX) - Defense World

Dec 07, 2024

Dec 05, 2024

Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register

Dec 05, 2024

Unveiling 5 Analyst Insights On Tango Therapeutics - Benzinga

Dec 05, 2024

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth? - Simply Wall St

Dec 05, 2024

Dec 03, 2024

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 03, 2024

Nov 29, 2024

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 21.7% - MarketBeat

Nov 29, 2024

Nov 27, 2024

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire

Nov 27, 2024

Nov 23, 2024